4basebio PLC Share Price OTC Markets
Stocks
FBSB.F
GB00BMCLYF79
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 87.4M 116M 102M 96.31M 164M 11.12B 165M 1.15B 445M 5.67B 434M 425M 18.24B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 87.99M 117M 103M 96.95M 165M 11.19B 166M 1.16B 448M 5.71B 437M 428M 18.36B | EV / Sales 2026 * |
85.8x | EV / Sales 2027 * | 22.9x |
| Free-Float |
38.75% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Amy Walker
CEO | Chief Executive Officer | 33 | 09/02/2026 |
Daniel Jones
CTO | Chief Tech/Sci/R&D Officer | - | 28/02/2025 |
Scott Lorimer
COO | Chief Operating Officer | - | 11/03/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Heikki Lanckriet
BRD | Director/Board Member | 48 | 21/12/2020 |
Amy Walker
BRD | Director/Board Member | 33 | 07/08/2024 |
| Chairman | 60 | 07/07/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 116M | |
| +2.64% | +7.07% | +11.87% | +38.40% | 47.97B | |
| +0.22% | +1.71% | +50.91% | +34.00% | 44.5B | |
| -1.58% | +5.65% | +359.34% | +598.06% | 43.93B | |
| +1.70% | +4.61% | +12.56% | +90.97% | 41.03B | |
| +0.51% | -0.61% | +5.18% | +46.87% | 29.85B | |
| -0.48% | +0.59% | +23.98% | +148.36% | 17.27B | |
| +0.08% | +9.30% | +8.41% | - | 15.34B | |
| +1.76% | +2.98% | +29.13% | +45.78% | 15.3B | |
| +1.97% | -2.82% | - | - | 14.82B | |
| Average | +0.68% | +2.46% | +62.67% | +143.21% | 30B | |
| Weighted average by Cap. | +0.74% | +2.97% | +79.47% | +158.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.02M 1.36M 1.19M 1.13M 1.93M 130M 1.94M 13.53M 5.22M 66.54M 5.1M 4.99M 214M | 5M 6.63M 5.83M 5.51M 9.39M 636M 9.44M 66.01M 25.45M 325M 24.85M 24.34M 1.04B |
| Net income | -18.2M -24.12M -21.21M -20.05M -34.19M -2.31B -34.36M -240M -92.63M -1.18B -90.47M -88.6M -3.8B | - |
| Net Debt | 584K 775K 681K 644K 1.1M 74.33M 1.1M 7.72M 2.97M 37.94M 2.91M 2.85M 122M | 27.1M 35.92M 31.58M 29.86M 50.9M 3.45B 51.16M 358M 138M 1.76B 135M 132M 5.65B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
